COVID-19 and Cancer: Discovery of Difference in Clinical Immune Indexes.
COVID-19 and Cancer: Discovery of Difference in Clinical Immune Indexes.
复制标题
COVID-19 和癌症：临床免疫指数差异的发现
DOI：
10.1155/2021/8669098
复制
发表时间：
2021
影响因子：
4.1
通讯作者：
Li Y
中科院分区：
文献类型：
--
作者：
Zeng X;Jiang X;Yang L;Pan Y;Li Y
本研究探讨了COVID-19患者与癌症患者之间免疫细胞和细胞因子的一致性和差异。我们进一步分析了急性炎症与癌症相关免疫紊乱之间的相关性。这项回顾性研究涉及167名COVID-19患者和218名癌症患者。COVID-19和癌症进一步分为两个亚组。定量变量和定性变量分别采用单因素方差分析和卡方检验。在此，我们进行了免疫细胞与细胞因子的相关性分析，并使用受试者工作特征（ROC）曲线来寻找最佳诊断指标。COVID-19和癌症与淋巴细胞减少和高水平的单核细胞、中性粒细胞、IL-6和IL-10有关。IL-2是鉴别两种疾病的最佳指标。与呼吸道肿瘤患者相比，COVID-19患者IL-2水平较低，CD3+CD4+ T细胞和CD19+ B细胞水平较高。在亚组分析中，IL-6是能够识别COVID-19患者是否会严重影响的最佳鉴别诊断参数，重症COVID-19患者淋巴细胞亚群（CD3+ T细胞、CD3+CD4+ T细胞、CD3+CD8+T细胞和CD19+ B细胞）和CD16+CD56+ NK细胞水平较低，中性粒细胞水平较高。T1-2期和T3-4期患者的CD3+CD4+ T细胞和CD19+ B细胞水平、N0-1期和N2-3期患者的IL-2和CD19+ B细胞水平差异均有统计学意义，而转移性和非转移性肿瘤患者的IL-2和CD19+ B细胞水平差异无统计学意义。此外，COVID-19患者IL-2和IL-4、TNF-α和IL-2、TNF-α和IL-4、TNF-α和IFN-γ、CD16+CD56+NK细胞和各种T细胞亚群之间存在较高的相关性。肿瘤患者CD3+CD4+ T细胞与CD19+ B细胞的相关性较高。与COVID-19或癌症相关的炎症对患者的预后有影响。伴随着免疫细胞和细胞因子的变化，COVID-19患者与癌症患者之间存在一致性、差异性和令人满意的相关性。
This study explored the consistency and differences in the immune cells and cytokines between patients with COVID-19 or cancer. We further analyzed the correlations between the acute inflammation and cancer-related immune disorder. This retrospective study involved 167 COVID-19 patients and 218 cancer patients. COVID-19 and cancer were each further divided into two subgroups. Quantitative and qualitative variables were measured by one-way ANOVA and chi-square test, respectively. Herein, we carried out a correlation analysis between immune cells and cytokines and used receiver operating characteristic (ROC) curves to discover the optimal diagnostic index. COVID-19 and cancers were associated with lymphopenia and high levels of monocytes, neutrophils, IL-6, and IL-10. IL-2 was the optimal indicator to differentiate the two diseases. Compared with respiratory cancer patients, COVID-19 patients had lower levels of IL-2 and higher levels of CD3+CD4+ T cells and CD19+ B cells. In the subgroup analysis, IL-6 was the optimal differential diagnostic parameter that had the ability to identify if COVID-19 patients would be severely affected, and severe COVID-19 patients had lower levels of lymphocyte subsets (CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+T cells, and CD19+ B cells) and CD16+CD56+ NK cells and higher level of neutrophils. There were significant differences in the levels of CD3+CD4+ T cells and CD19+ B cells between T1-2 and T3-4 stages as well as IL-2 and CD19+ B cells between N0-1 and N2-3 stages while no significant differences between the metastatic and nonmetastatic cancer patients. Additionally, there were higher correlations between IL-2 and IL-4, TNF-α and IL-2, TNF-α and IL-4, TNF-α and IFN-γ, and CD16+CD56+NK cells and various subsets of T cells in COVID-19 patients. There was a higher correlation between CD3+CD4+ T cells and CD19+ B cells in cancer patients. Inflammation associated with COVID-19 or cancer had effects on patients' outcomes. Accompanied by changes in immune cells and cytokines, there were consistencies, differences, and satisfactory correlations between patients with COVID-19 and those with cancers.
登录
查看更多内容
影响因子：
28.3
作者：
Gorbalenya, Alexander E.;Baker, Susan C.;Ziebuhr, John
通讯作者：
Ziebuhr, John
影响因子：
64.5
作者：
Karki R;Sharma BR;Tuladhar S;Williams EP;Zalduondo L;Samir P;Zheng M;Sundaram B;Banoth B;Malireddi RKS;Schreiner P;Neale G;Vogel P;Webby R;Jonsson CB;Kanneganti TD
通讯作者：
Kanneganti TD
影响因子：
13.8
作者：
Wu, Huan;Zhu, Hongmin;Xiang, Yun
通讯作者：
Xiang, Yun
开发和验证基于免疫炎症的指数，用于预测鼻咽癌患者的临床结果。
影响因子：
5.3
作者：
Zeng, Xiaojiao;Liu, Guohong;Li, Yirong
通讯作者：
Li, Yirong
DOI：
10.26355/eurrev_202012_24051
发表时间：
2020-12-01
影响因子：
3.3
作者：
Li, Q.;Xu, W.;Chen, L.
通讯作者：
Chen, L.